Haemorheology and cerebrovascular disease: multifunctional approach with pentoxifylline
- PMID: 7014106
- DOI: 10.1185/03007998109114271
Haemorheology and cerebrovascular disease: multifunctional approach with pentoxifylline
Abstract
New aspects in the pathophysiology of chronic cerebral ischaemia as the cause of the multiform syndromes of cerebrovascular disorders are reviewed and therapeutic approaches are discussed. It is suggested that the fatal vicious circles of the disturbances of nutritive blood flow within the decompensated cerebral microcirculation can by interrupted by pentoxifylline. By amelioration of the disturbed flow properties of blood in the affected capillary regions through inhibition of red cell and platelet aggregation, improvement of red cell deformability and reduction in blood viscosity, oxygen supply is enhanced and more glucose is made available. Membrane permeability and function of the cell are normalized by the favourable inhibitory action of pentoxifylline on oedematous changes in the brain tissue and mechanical obstacles in the micro-circulation are removed. The disturbed cerebral metabolism is directly stimulated by compensation of the impaired energetic balance. The combined rheological, antioedematous and metabolic effects of pentoxifylline offer a multifunctional therapy of cerebrovascular circulatory disorders.
Similar articles
-
Cerebrovascular circulatory disorders: new aspects of pathophysiology and therapy.J Med. 1979;10(5):347-64. J Med. 1979. PMID: 393790 Review.
-
Pentoxifylline and cerebrovascular diseases.Eur Neurol. 1983;22 Suppl 1:89-97. doi: 10.1159/000115656. Eur Neurol. 1983. PMID: 6350013 Review.
-
Pentoxifylline -- a biomedical profile.J Med. 1979;10(5):307-29. J Med. 1979. PMID: 393789 Review.
-
Effect of pentoxifylline on cerebral blood flow in patients with chronic cerebrovascular disease.J Int Med Res. 1981;9(3):211-4. doi: 10.1177/030006058100900311. J Int Med Res. 1981. PMID: 7238996
-
Pentoxifylline increases cerebral blood flow in patients with cerebrovascular disease.Stroke. 1989 Dec;20(12):1662-6. doi: 10.1161/01.str.20.12.1662. Stroke. 1989. PMID: 2512690
Cited by
-
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.Drugs. 1987 Jul;34(1):50-97. doi: 10.2165/00003495-198734010-00003. Drugs. 1987. PMID: 3308412 Review.
-
Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases.Drugs. 1987 May;33(5):430-60. doi: 10.2165/00003495-198733050-00002. Drugs. 1987. PMID: 3297620 Review.
-
Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.Psychopharmacology (Berl). 1990;101(2):147-59. doi: 10.1007/BF02244119. Psychopharmacology (Berl). 1990. PMID: 2190256 Review.
-
Pentoxifylline as adjunct therapy to long-term clinical management of a right-to-left patent ductus arteriosus.Can Vet J. 2016 Jun;57(6):655-6. Can Vet J. 2016. PMID: 27247468 Free PMC article.
-
Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.Cancer Chemother Pharmacol. 1991;28(1):45-50. doi: 10.1007/BF00684955. Cancer Chemother Pharmacol. 1991. PMID: 1904012
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources